Oncolytics Biotech Inc. Files 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Jul 10, 2025 · CIK: 1129928

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer

TL;DR

ONCOLYTICS BIOTECH FILES 6-K REPORT - REGULAR UPDATE FOR INVESTORS.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on July 10, 2025, reporting as a foreign private issuer for the month of July 2025. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing indicates they are submitting reports under the 1934 Act and will file annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Oncolytics Biotech's status as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of July 2025.

What is the company's principal executive office address?

The company's principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

Which annual report form does Oncolytics Biotech Inc. indicate it files?

The company indicates it files annual reports under cover of Form 20-F.

What is the SIC code for Oncolytics Biotech Inc.?

The Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.

On what date was this Form 6-K filed?

This Form 6-K was filed on July 10, 2025.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 10, 2025 regarding ONCOLYTICS BIOTECH INC (ONCY).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing